A researcher from Bodoland University reports on a study investigating the binding property of ivermectin on four critical drug targets, including 1) spike protein, 2) RNA-dependent RNA polymerase, 3) 3-chymotrypsin-, and 4) papain-like proteases of SARS-CoV-2, the virus behind the COVID-19 pandemic. After conducting preclinical “in silica” investigations, the researcher’s docking study evinces that ivermectin was superior to lopinavir, as a binding drug against SARS-COV-2. The researcher found that not only did twenty-one amino acid residues of RdRp interact with ivermectin (including Asp760) but also RNA-RdRp complex demonstrated that the catalytic active residues Ser759 and Asp760 of RdRp created robust interactions with RNA chain. The author suggests evidence that ivermectin inhibits SARS-COV-2 replication as the antiparasitic drug binding in the active site of RdPp clashes with RNA chain nucleotides. The author concludes that ivermectin possibly inhibits RdRp possibly a crucial feature combatting SARS-CoV-2 and perhaps a reason for the growing positive findings when used to treat COVID-19.
Bodoland University, a state university located in Debargaon...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).